Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CCI-779 in B-cell Lymphoma and CLL

NCT00290472 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00290472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CCI-779 in B-cell Lymphoma and CLL
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
April 30, 2010
Enrollment
89 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, malignant neoplasm, nodal marginal zone b-cell lymphoma, recurrent adult burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, splenic marginal zone lymphoma, waldenström macroglobulinemia